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Abstract 
 
The main objective of this paper is to evaluate possible socio-economic status, clinical, and 
treatment associations with the occurrence of distant metastasis in Stage I – III breast cancer 
patients.    After analysis in a logistic regression model, four variables were found to be 
significant with occurrence of distant metastases.  These variables were: education, disease group 
(Triple-negative, Her2Neu-positive and Luminal A), stage at diagnosis, and concordance to 
chemotherapy based on the NCCN guidelines.  Patients without a college degree were found to 
be more likely to develop distant metastasis than those with a college degree (OR = 2.46 95% CI 
1.44 – 4.23).  Triple-negative and Her2Neu-positive patients had higher odds of having distant 
metastasis than those in with luminal A disease (OR = 3.88 and 3.22 95% CI 2.25 – 6.69 and 
1.88 – 5.52, respectively).  Stage III patients also had higher odds of having distant metastasis 
than those with Stage I disease (OR = 5.41 95% CI 2.74 – 10.65).  Finally, an unusual result was 
discovered where patients who were not classified to a chemotherapy guideline were 
significantly less likely to have distant metastasis than their counterparts who received the 
recommended chemotherapy (OR = .32 95% CI 0.17 - 0.58).  
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1.  Introduction 
 
Cancer is a disease of growing concern in today’s world.  New research is done every day in an 
attempt to discover more about this disease and how it works.  There is no doubt that many 
questions regarding cancer are unanswered.  There is a great need for research on this subject to 
find out better ways to treat and cure cancer patients.  This research project focuses on breast 
cancer, specifically distant metastasis, and attempts to answer questions about the characteristics 
a patient may have in relation to distant metastasis.  A distant metastasis is defined as cancer that 
has spread from the original (primary) tumor to distant organs or distant lymph nodes.  In this 
case, a distant metastasis would mean the cancer has spread to an area other than the breast (the 
primary site). 
 
There were two main research questions investigated in this analysis.  The first was whether 
triple-negative breast cancer is associated with developing a distant metastasis.  The second was 
whether a patient’s type of treatment is associated with developing a distant metastasis.  
Typically, triple-negative patients are harder to treat because of their unique status, so it was 
thought that this group might be associated with higher probability of getting a distant 
metastasis.  In addition, it was thought that patients who received both radiation and 
chemotherapy, instead of just one or the other, might have a lower probability of developing 
distant metastasis.  Other variables were included in the analysis as controls and/or additional 
variables of interest.  These variables included information about socio-economic status, clinical, 
and treatment.   
 
The data for this analysis was based on a sample of patients from the City of Hope National 
Medical Center.  The data is stored in the National Comprehensive Cancer Network (NCCN) 
Outcomes Database.  This database consists of many different data tables, each with many 
different variables within the table.  Data is grouped in “raw” data sets that are just pure data as 
entered into the database and also “derived” data sets that are created from the raw data using 
predefined programming algorithms.  All data is stored in a SQL database and downloaded into 
SAS data sets that use a hierarchal data structure.  Each data set has a corresponding data 
dictionary which was reviewed to identify variables of interest.  The focus for this analysis was a 
group of patients diagnosed with stage I-III breast cancer and the objective was to choose and 
test the significance of possible variables that might have an association with whether a breast 
cancer patient experiences a distant metastasis, using logistic regression.   
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2. Data Cleaning and the Final Data Set 
 
A major component of this project included programming in SAS to read in data, make 
necessary exclusions, obtain variables of interest, and create new variables from existing ones for 
analysis.  In order to make the data manageable, the data sets had to be reviewed to identify the 
cohort and variables of interest.  Only certain data sets were read into SAS and then merged to 
create the final cohort data set. 
 
2.1 Exclusions and Controls 
 
In order to carry out an accurate analysis, exclusions had to be made.  Some patients were 
excluded right when the data was read in to SAS.  This included patients who did not have 
enough follow-up for an analysis that involved radiation therapy (270 days from presentation).  
Some patients had second episodes of breast cancer, so observations were limited to the first 
occurrence of cancer and patients with bilateral disease were also excluded.  The goal was to 
investigate treatment and disease group effects on metastases, so any patients with no treatment 
information were to be deleted.  Only patients with treatment defined as adjuvant therapy 
(treatment given after the primary surgery) and neo-adjuvant therapy (treatment given prior to 
the primary surgery to shrink the tumor) were included, since these treatments are given to lower 
the risk of recurrence.  Since the other primary goal of the analysis was to identify if disease 
group is associated with distant metastasis, patients with missing or unknown estrogen or 
progesterone receptor or Her2Neu status were excluded, because they would not be able to be 
classified into a disease grouping. 
 
Stage IV patients were excluded because they are a different subset of people.  These patients 
have metastases at diagnosis, where the stage I-III patients do not.  Stage IV patients are usually 
terminal and too far along in the disease to be considered in an analysis looking at predictors of 
distant recurrence.  Since the primary interest was in the characteristics that help predict if a 
patient gets distant metastasis, it does not make sense to include Stage IV patients that have 
already metastasized.  Stage 0 patients were also excluded because chemotherapy, one of the 
treatments of interest in this analysis, is not usually given to this group of patients.  Stage 0 
patients are typically treated as a preventative measure and thus did not fit in to the cohort.  Out 
of the 2,200 total patients in the data set, 964 fit the criteria and were included in the analysis. 
 
2.2 SAS Programming 
 
The first step in the programming process was to identify all variables of interest from the 
various data dictionaries.  Patients were excluded that did not fit the criterion as described in the 
previous section.  A total of 11 different data sets were used in this analysis.  These data sets are 
grouped in a hierarchical database model, meaning that the data is organized into a tree-like 
structure and linked together by keys.  All of the data sets have a common key variable, patient 
ID (pid), and some share diagnosis ID (dxid) and possibly  tumor ID (tumorid) key variables as 
well.  The patients are identified by pid and then each different diagnosis is identified by dxid 
within the pid key.  In addition, the tumorid key identifies different tumors within each 
diagnosis.  Since many of the data sets contain information on patients with recurrence or more 
than one tumor, there is the possibility for more than one record per patient.  In this case, these 
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records are organized by the dxid and tumorid variables within each pid.  However, some of the 
data sets are already narrowed down to one record per patient, like the demographics data sets.  
Because of this, data sets had to be sorted and merged in a specific manner in order to get the 
correct information based on one record per patient.  Table 1 summarizes the variables and the 
corresponding tables they were found in. 
 
Table 1: Data Sets and Variables 
Data Set Variables Key Variables 
Patient Characteristics (derived) Age at Diagnosis, Income, Race, Follow-Up Radiation Therapy Flag pid 
Clinical Characteristics (derived) Final Stage pid, dxid, tumorid 
Adjuvant Drug Therapy (derived) Flags for Adjuvant Treatment Group pid, dxid 
Metastasis Patient Characteristics 
(derived) Age at Metastasis pid, dxid 
Surgical Information (derived) Definitive Surgery Group pid, dxid, tumorid 
Metastatic Sites (raw) Distant Metastasis variables pid, dxid 
Study Accession (raw) Education Level, Employment Status, Height, Weight pid 
Insurance (raw) Insurance Provider pid 
Solid Tumor Stage (raw) Radiation Flags and Disease Group pid, dxid, tumorid 
Treatment (raw) Radiation Flags and Neo-adjuvant/Adjuvant Flags pid, dxid 
Concordance (derived) Concordance Information pid, dxid, tumorid 
 
Within these data sets, code was used to manipulate and create new variables to be used in the 
model.  In the Adjuvant Drug Therapy data set, a binary variable was created for whether or not 
a patient had chemotherapy.  The Metastasis Patient Characteristics data was used to create a 
variable for time to metastasis from original diagnosis.  As described later, this variable was 
intended for use in a subsequent analysis. The Metastatic Sites data set included variables that 
were used to determine where the metastasis occurred and a variable (the response variable) was 
created for whether or not a patient had distant metastasis or not. The Solid Tumor Stage data set 
provided useful data for laterality of the patient’s breast cancer and for creating a categorical 
variable for a patient’s disease group based on certain clinical characteristics.  The raw 
Treatment data set provided data to classify patients into neo-adjuvant/adjuvant radiation 
treatment groupings and to ensure patients were only flagged for radiation treatment if the 
treatment side was equal to the laterality of the breast cancer.  
 
Finally, to create the most complex variables, the derived Concordance data set was used to 
manipulate the concordance variables for each patient.  Since it is possible for patients to be put 
on several guidelines, some patients had multiple observations to account for concordance on 
different guidelines.  The concordance data set contained variables for concordance (Yes/No/Not 
evaluated), guideline, version, and reason if the patient was not concordant.  The data was 
transposed to get a row for each corresponding concordance, guideline, version, and reason 
variable for each patient.  The data was then merged with itself to create one row per patient and 
four sets of each of the four concordance variables (since any patient is on at most four 
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guidelines).   The following merge creates a four columns, one for each guideline a patient may 
be on.  This was repeated for each of the three other variables. 
 
**Merge data with itself to get one record per patient; 
data Mconcord; 
merge trconcord (where=(_NAME_='guideline') keep=pid dxid tumorid 
_NAME_ col1-col4 rename=(COL1=Guideline1) rename=(COL2=Guideline2) 
rename=(COL3=Guideline3)rename=(COL4=Guideline4)) 
... 
by pid dxid tumorid; 
run; 
 
The last step in the initial programming was to combine and merge all of the relevant data sets 
into one final data set with the variables of interest.  Care had to be taken to combine data sets 
with the set of common keys first starting at the tumor level (pid, dxid, tumorid).  Then this 
result could be combined with those data sets at the next level (pid and dxid), and finally 
combined with those data sets that just use pid as a key.  Several sets of merges with trackers 
were used to accomplish this.  In addition, binary variables were created at the appropriate parts 
of the program to indicate if a patient had radiation treatment and/or a distant metastasis.  For 
example, if the patient had a missing value for metastatic site, then the patient was recorded as 
having no metastasis.  At the end, the final data set was reviewed to ensure there was only one 
record per patient. 
 
2.3 Predictors 
 
Once the final patient level data set was created, an analysis data set was made.  In this analysis 
data set, variables were created and manipulated so that they could be used in the logistic 
regression models.  A body mass index (BMI) variable was created from the height and weight 
data, as well as a categorical variable based on BMI.  Many of the predictors, such as age, were 
collapsed into interesting groups that were clinically meaningful.  Breakpoints of <50 (pre-
menopause), 50-<70 (midrange) and 70+ (older) were chosen due to their relationship with 
breast cancer care at a biological and clinical level.  Continuous variables were tested for 
linearity in the logit and categorical variables were included if the variable met the appropriate 
assumptions for the analysis.  Groups for categorical variables were collapsed, defined by what 
seemed to make sense and would be easy to understand and interpret.  Collapsing these 
categorical variables prevented convergence issues from having too few observations in any one 
group.  The analytic data set is also where final exclusions were made, such as patients who were 
stage IV at diagnosis.  Instead of deleting excluded patients, they were output to a second data 
set to double check that patients were excluded for correct reasons. 
 
In order to be able to use logistic regression, the response variable (distant metastasis) was 
collapsed into two groups.  One group was patients who experienced distant metastasis, and the 
other was patients who experienced local metastasis or no metastasis.  For ease of discussion of 
the predictor variables, they were grouped into three categories/types: personal and socio-
economic status characteristics, clinical characteristics, and treatment characteristics. 
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The personal and socio-economic status variables included: age at diagnosis, body mass index 
(BMI), BMI group, race, insurance, education level, employment status, and income.  Age at 
diagnosis was tested for linearity in the logit by using a Box-Tidwell transformation, and failed.  
BMI was tested for linearity in the logit using the same method, and passed.  However, as stated 
earlier, BMI was not significant as a continuous predictor, so it was grouped by clinically 
meaningful cutoffs for underweight, normal, overweight, and obese, and then tested as a 
categorical variable as well.  Race was collapsed into the three largest groups: Caucasian, 
Hispanic, and African American.  A fourth group, “Other,” was added for those who did not fall 
into any of those categories.  Insurance was broken up into four groups: Managed Care, 
Medicare, Medicaid, and other.  Education level was collapsed into three categories: college 
degree (college, some college/AA and graduate school), no college degree, and unknown/other.  
Employment status was broken up into employed (including employed students), student, and 
other. Table 2 provides a summary of these variables.  
 
Table 2: Personal and Socio-Economic Status Characteristics1 
1 Continued on next page 
 
 
 
 
 
Variable Group 
Local or No 
Metastasis 
(N=863) 
n (%) 
Distant 
Metastasis 
(N=101) 
n (%) 
Total 
(N=964) 
n (%) 
-- Mean: 53.5 Median: 52.8 
Mean: 53.1 
Median: 51.3 
Mean: 53.5 
Median: 52.6 
Below 50 352 (40.8) 43 (42.6) 395 (41.0) 
50-70 439 (50.9) 42 (41.6) 481 (50.0) 
Age at Diagnosis 
Above 70 72 (8.3) 16 (15.8) 88 (9.1) 
-- Mean: 27.4 Median: 26.5 
Mean: 28.7 
Median: 27.6 
Mean: 27.5 
Median: 26.6 
Underweight 18 (2.09) 1 (0.99) 19 (1.97) 
Normal 320 (37.08) 27 (26.73) 347 (36.00) 
Overweight 281 (32.56) 36 (35.64) 317 (32.88) 
BMI 
Obese 244 (28.27) 37 (36.63) 281 (29.15) 
Caucasian 452 (52.38) 54 (53.47) 506 (52.49) 
Hispanic 230 (26.65) 29 (28.71) 259 (26.87) 
African American 46 (5.33) 6 (5.94) 52 (5.39) Race 
Other 135 (15.64) 12 (11.88) 147 (15.25) 
Managed 480 (55.62) 42 (41.58) 522 (54.15) 
Medicare 139 (16.11) 23 (22.77) 162 (16.80) 
Medicaid 234 (27.11) 35 (34.65) 269 (27.90) Insurance 
Other 10 (1.16) 1 (0.99) 11 (1.14) 
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Table 2 Continued: Personal and Socio-Economic Status Characteristics 
Variable Group 
Local or No 
Metastasis 
(N=863) 
n (%) 
Distant 
Metastasis 
(N=101) 
n (%) 
Total 
(N=964) 
n (%) 
College Degree 411 (47.62) 23 (22.77) 434 (45.02) 
No College 339 (39.28) 50 (49.50) 389 (40.35) Education Level2 
Unknown 113 (13.09) 28 (27.72) 141 (14.62) 
Student 8 (0.93) 2 (1.98) 10 (1.04) 
Employed 391 (45.31) 37 (36.63) 428 (44.40) 
 
Employment 
Status Other 464 (53.77) 62 (61.39) 526 (54.56) 
Income -- 
Mean: 
$52,251.31 
Median: 
$50,047.00 
Mean: 
$48,066.07 
Median: 
$42,108.00 
Mean: 
$51,820.80 
Median: 
$49,818.00 
2 Italicized variables in Tables 2-4 were significant in the final model 
 
The clinical variables were stage at diagnosis and disease group.  The stage at diagnosis variable 
was collapsed into stage I, II or III.  Of these groups, stage I patients are the least advanced and 
stage III patients are the most advanced.  A disease group variable was created based on estrogen 
receptor (ER) status, progesterone receptor (PR) status, and Her2Neu status.  ER, PR and Her2 
are markers on cancer cells that identify how a patient will respond to different therapies.  A 
patient was classified as triple-negative if ER is negative, PR is negative, and Her2Neu status is 
negative or low positive.  A patient was classified as Her2Neu-positive if Her2Neu status is high 
positive or positive NOS, regardless of ER and PR status.  A patient was classified as luminal A 
if they did not fit in to any of the previously mentioned groups.  Table 3 shows a summary of 
these variables. 
 
Table 3: Clinical Characteristics  
 
The treatment variables included: definitive surgery group, radiation and/or chemotherapy 
treatment group, and concordance to NCCN guidelines.  Definitive surgery group was defined 
as: breast conserving surgery, mastectomy, or no cancer directed surgery.  The treatment group 
variable was created to indicate whether a patient had only chemotherapy, only radiation, or 
both.  The concordance variable was created to indicate whether the patient received the 
Variable Group 
Local or No 
Metastasis 
(N=863) 
n (%) 
Distant 
Metastasis 
(N=101) 
n (%) 
Total 
(N=964) 
n (%) 
I 262 (30.36) 15 (14.85) 277 (28.73) 
II 433 (50.17) 42 (41.58) 475 (49.27) Stage at Diagnosis III 168 (19.47) 44 (43.45) 212 (21.99) 
Triple-negative 134 (15.53) 33 (32.67) 167 (17.32) 
Her2Neu-
positive 170 (19.70) 34 (33.60) 204 (21.12) Disease Group 
Luminal A 559 (64.77) 34 (33.66) 593 (61.51) 
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treatment they were recommended to receive by the NCCN guidelines.  Each patient is placed on 
as many guidelines as they are eligible for.  The guidelines are different pathways that a patient 
can be classified on based on their clinical characteristics.  These guidelines can recommend 
different modalities of treatment including chemotherapy, radiation therapy, and/or other 
treatment.  For this analysis, patients were could only be on a radiation and/or chemotherapy 
guideline or no guideline because of the exclusions that were made.  The concordance variable 
used in this analysis indicates whether or not the patient followed the care of the given guideline 
that they were on.  Table 4 contains summaries for these clinical variables. 
 
Originally, one concordance variable was created that considered both radiation and 
chemotherapy together.  The variable was first broken up into many specific categories for 
combinations of chemotherapy and radiation concordance.  However, during analysis, SAS gave 
an error due to quasi-complete separation of the data points.  The concordance variable was then 
collapsed into groups for concordant chemotherapy and radiation, concordant radiation (not 
considering whether or not the patient had a discordant chemotherapy or not on a chemotherapy 
guideline), concordant chemotherapy (again, not considering discordant radiation or not on a 
radiation guideline), and not concordant at all.  Again, the concordance variable gave some 
unusual results which were difficult to interpret.  So the variable was then split into two 
variables, one based on chemotherapy and one based on radiation therapy, to investigate where 
the odd behavior was coming from.  A concordance variable was defined for patients on a 
radiation therapy guideline (yes, no, n/a for concordance) and another variable for patients on a 
chemotherapy guideline (same categories).  From these variables, the analysis was able to 
pinpoint which therapy was significant, if any.   
 
 Table 4: Treatment Characteristics  
Variable Group 
Local or No 
Metastasis 
(N=863) 
n (%) 
Distant 
Metastasis 
(N=101) 
n (%) 
Total 
(N=964) 
n (%) 
Breast 
Conserving 
Surgery (BCS) 
484 (56.08) 46 (45.54) 530 (54.98) 
Mastectomy 367 (42.53) 53 (52.48) 420 (43.57) 
Definitive 
Surgery Group 
No Definitive 
Surgery 12 (1.39) 2 (1.98) 14 (1.45) 
Chemotherapy 
Alone 213 (24.68) 26 (25.74) 239 (24.79) 
Radiation Alone 174 (20.16) 8 (7.92) 182 (18.88) Treatment Group 
Chemotherapy 
and Radiation 476 (55.06) 67 (66.34) 543 (56.33) 
Yes 465 (53.88) 61 (60.40) 526 (54.56) 
No 157 (18.19) 18 (17.82) 175 (18.15) Chemotherapy Concordance N/A 241 (27.93) 22 (21.78) 263 (27.28) 
Yes 488 (56.55) 45 (44.55) 533 (55.29) 
No 45 (5.21) 9 (8.91) 54 (5.60) Radiation Concordance N/A 330 (38.24) 47 (46.53) 377 (39.11) 
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The concordance variable required creative programming in order to create the variable since the 
sets of guideline and concordance variables had to be examined and combined to create one 
variable.  As previously described, concordance and guideline each had a set of four variables for 
each patient.  To create the chemotherapy and radiation concordance variables, arrays were set-
up for the guideline and concordance variables.  In a do loop, each guideline was tested for type 
of therapy recommended and the corresponding concordance was extracted.  The concordance 
variables were increased by one if the patient was concordant.  For example: 
 
do i=1 to 4; 
  if conc(i)='Yes' and (substr(guide(i),1,4)='invx' or 
guide(i)='invtx1' or guide(i)='invtx1b' or guide(i)='invtx1c')  
 then RTConcord=rtconcord+1; 
if conc(i)='Yes' and (substr(guide(i),1,4)='inva' or 
guide(i)='invtx1' or guide(i)='invtx1b' or guide(i)='invtx1c' or 
guide(i)='invtx1a' or guide(i)='invtx2')  
   then ChemoConcord=chemoconcord+1; 
end; 
 
After deciding when a patient was concordant, there had to be a way to break up not concordant 
patients and the “not applicable” patients.  At this point, patients either had a value of 1 if they 
were concordant or 0 if they were not concordant or not applicable.  These “N/A” patients 
included those that were not evaluated for concordance or were put on a different guideline not 
relevant to the given modality.  This occurs when a patient does not have the clinical 
characteristics specific to a guideline.   In order to break up the groups, another do loop was 
created to check the two sets of four variables.  The loop would only start if the patient did not 
have a “Yes” for either concordance variable.  The following code was used to break up these 
groups: 
 
if (chemconcord=0 or rtconcord=0) and guide(1)~='Not evaluated for  
  concordance' then do i=1 to 4; 
 if conc(i)='No' and (substr(guide(i),1,4)='invx' or guide(i)='invtx1'  
   or guidei)='invtx1b'  
   or guide(i)='invtx1c')  
  then rtconcord=2; 
 if conc(i)='No' and (substr(guide(i),1,4)='inva' or guide(i)='invtx1'  
  or guide(i)='invtx1b'  
   or guide(i)='invtx1c' or guide(i)='invtx1a' or guide(i)='invtx2')  
  then chemconcord=2; 
end; 
 
After the do loop and testing for non-concordance, the concordance variables ended up with a 
value of 1 if the patient was concordant, a value of 2 if the patient was not concordant, and a 
value of 0 of the patient was not on a guideline. 
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3. Analysis 
 
Once the final analytic data set was created, PROC FREQ was run on categorical predictors and 
PROC MEANS was run on continuous predictors to get a sense of the data and indicate any 
missing values.  These results are summarized in the three tables shown in the previous section.  
In SAS, PROC LOGISTIC was used to run logistic regression models and investigate 
relationship between the predictors of interest and the distant metastasis response variable.  The 
outcome modeled was distant metastases equal to yes, so the odds ratio interpretations are thus 
predicting the odds of a patient getting distant metastasis.  Since most of the predictors were 
categorical, reference groups had to be assigned for each variable.  These reference groups were 
defined based on what clinically would be least likely to result in distant metastasis for ease of 
interpretation of the results.  This means that the groups of greatest interest (more likely to get 
distant metastasis) would have a predictor coefficient in the model.  For example, Stage “I” was 
chosen as the reference group for the stage variable since Stage I patients are less advanced and 
thus were predicted to be less likely to get a distant metastasis.  In addition, “Luminal A” was 
chosen as the reference for disease group, “College degree” was chosen as the reference for 
education, and “Yes” was chosen as the reference group for the Concordance variables. 
 
In addition to testing all the covariates, possible interactions were also considered.  Instead of 
relying on a stepwise regression to come up with interactions that might not make sense 
clinically, meaningful interactions were established a priori and then tested in the model.  First, 
the clinically meaningful interactions were tested, such as age with treatment group, treatment 
group and disease group, and various other combinations.  However, all of the interactions tested 
turned out to be insignificant. In the end, stepwise selection was used as a back-up in case any 
significant interactions were missed, but still, none came up as significant and it was decided that 
the effect of any of the predictors did not depend on other predictors. 
 
Three models were considered: a saturated model with all covariates of interest, a significant 
borderline model with all covariates that had a p-value <0.10, and a significant terms only model.  
The saturated model included many insignificant variables and did not turn out to be a useful 
model.  From the saturated model, least significant variables were removed one at a time until all 
variables fit within the significance level desired.  The final significant model included one 
socio-economic variable for education level, two clinical variables for disease group and stage, 
and one treatment variable for chemotherapy concordance.  The borderline model also included 
the categorical age group variable and continuous BMI variable in addition to the significant 
model predictors, however these variables did not add much more information to the model.  The 
significant model was used as the final model as reported in this paper. 
 
3.1 Assumptions  
 
One of the biggest advantages of logistic regression is that there are not as many restrictive 
assumptions as in linear regression.  The first assumption is that there is linearity between the 
logits and explanatory variables.  However, since all of the significant predictors in the final 
model are categorical, this was not an assumption of concern in this analysis.  Independent 
observations are also needed, but since this data is from de-identified retrospective data 
collected, this was not something that could be controlled for during this analysis. However, it is 
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obvious that one patient getting a distant metastasis has nothing to do with another patient’s 
experience with distant metastasis and there also is no reason to think that the patients have any 
genetic relationships.  Large sample size is ideal for logistic regression and this was not a 
problem (with a final sample size of 964 patients) for this data set.  Another assumption is no 
multicollinearity between the explanatory variables, and no outliers.  These two assumptions will 
be addressed in the Diagnostics section of the paper.  Otherwise, no assumptions were violated. 
 
3.2 Results 
 
The final model included the variables for disease group, chemotherapy concordance, stage at 
diagnosis, and education level.  Table 5 provides a summary of odds ratio estimates and 
confidence intervals for each significant variable in the model. 
 
Table 5: Significant Model Estimates 
Variable Overall P-Value Group Odds Ratio Estimate 
95% Confidence 
Interval 
Luminal A Reference 
Her2Neu-positive 3.223 (1.884, 5.516) Disease Group <0.0001 
Triple-negative 3.881 (2.250, 6.694) 
Yes Reference 
No 0.911 (0.492, 1.686) Chemotherapy Concordance 0.0008 N/A 0.317 (0.173, 0.583) 
I Reference 
II 1.234 (0.650, 2.341) Stage at Diagnosis <0.0001 III 5.406 (2.744, 10.650) 
College Degree Reference 
No College 2.462 (1.435, 4.225) Education Level <0.0001 
Unknown 4.810 (2.571, 8.999) 
 
As seen in Table 5, the significance of the disease group variable provided an explanation to the 
first research question of interest.  Patients with triple-negative disease were estimated to be 3.88 
times more likely to develop a distant metastasis than those with luminal A (95% CI 2.25 – 
6.69).  Similarly, patients in the Her2Neu-positive disease group were also associated with 
higher odds of having distant metastasis than patients in the luminal A group (OR = 3.22 95% CI 
1.88 – 5.52). 
 
As previously mentioned, the concordance variable gave some unusual results.  But, the 
significance of the chemotherapy concordance provided some explanation for the second 
research question relating to a patient’s treatment.  Concordance was originally one variable that 
considered both radiation and chemotherapy.  Since this variable behaved unusually (with the 
N/A patients less likely to get distant metastasis), the variable was broken down into two 
variables, one for radiation concordance and one for chemotherapy concordance, to target where 
this problem was coming from.  The chemotherapy concordance turned out to be the culprit.  The 
radiation variable turned out not to be a predictor of distant recurrence and was not included in 
the final model.  As seen in Table 5, the “N/A” patients (those who were not evaluated for 
concordance or not on a guideline) were associated with being significantly less likely to have 
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distant metastasis than patients who were concordant for chemotherapy (OR = 0.32 95% CI 0.17 
– 0.58).  Patients who were not concordant were not significantly associated with developing 
distant metastasis than those who were concordant.   
 
Stage at diagnosis had one significantly different group, which were the Stage III patients.  Stage 
III patients were associated with 5.41 higher odds of having distant metastasis than Stage I 
patients (95% CI 2.74 – 10.65), after considering the other variables in the model.  Stage II 
patients were not significantly more or less likely to have distant metastasis than Stage I patients.   
 
Finally, education level was the only significant non-treatment or non-clinical variable.  Patients 
with no college education were 2.46 times more likely to develop distant metastasis than those 
with a college education (95% CI 1.44 – 4.23), considering the other covariates in the model.  
Similarly, patients with unknown education level also were estimated to have higher odds of 
getting distant metastasis than patients with a college degree (OR = 4.81 95% CI 2.57 – 9.00). 
Figure 1 provides a visual representation of the odds ratios for each level of the covariates.  The 
width of the band corresponds to the width of the 95% confidence interval. 
 
Figure 1: Odds Ratios Plot 
 
 
3.3 Diagnostics 
 
In order to ensure the validity of the model and to solidify any conclusions, it is essential to 
check model fit and other diagnostics.  SAS was used to run a Hosmer-Lemeshow Goodness-of-
Fit Test.  The result was a Chi-Square test statistic of 2.4116 with 8 degrees of freedom and a p-
value of 0.9657, which means that there is no evidence that this model is not a good fit to the 
data.  In addition, Deviance and Pearson Goodness-of-Fit Statistics for the logistic regression 
residuals were tested.  Deviance gave a value of 70.4679 with 68 degrees of freedom, which 
gave a ratio (value/df) of 1.0363 and a p-value of 0.3951.  Also, Pearson gave a value of 60.9382 
with 68 degrees of freedom, which is a ratio of 0.8961 and p-value of 0.7157.  Since the ratios 
were close to 1, there is no indication of severe under- or over-dispersion.  As there were no 
dispersion issues, there does not appear to be evidence that the binomial assumption is not valid 
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for this model.  SAS also gives an R2 value of 0.2057.  Although this value is not very 
impressive, this is sometimes the case with real patient based data and is not something to be 
very concerned with in this analysis.  
 
Multicollinearity among the predictors was tested using PROC CORR with the Spearman 
correlation coefficients, as the predictors were categorical variables.  Table 6 shows a summary 
of these results.  Some of the covariates have significant correlations, however this is usually the 
case with large sample sizes.  Since none of the correlations appear to be very large and standard 
errors of the estimates are low, multicollinearity does not seem to be an issue in this model. 
 
Table 6: Spearman Correlation Coefficients 
rs 
Prob>|rs| 
Disease Group Stage at Diagnosis Education Level 
Chemotherapy 
Concordance 
Disease Group 1.000 -0.114 0.0004 
-0.035 
0.2768 
0.126 
<0.0001 
Stage at 
Diagnosis 
-0.114 
0.0004 1.000 
0.087 
0.0069 
-0.282 
<0.0001 
Education Level -0.035 0.2768 
0.087 
0.0069 1.000 
0.024 
0.4482 
Chemotherapy 
Concordance 
0.126 
<0.0001 
-0.282 
<0.0001 
0.024 
0.4482 1.000 
 
Finally, unusual observations and case-influence diagnostics were investigated.  Figure 2 shows 
diagnostic plots for the model.  The top two plots are residual plots.  Note that the distinct 
separation of the residuals is due to the different response groups.  Distant metastasis patients 
have the positive residuals, while the no metastasis patients have the negative residuals.  If 
anything, the residual plots show a distinct difference between the no distant metastasis patients 
and the distant metastasis patients.  These plots also show a random scatter of points and there is 
no distinct curvature or pattern.  In this case, Pearson residuals are equivalent to the standardized 
Pearson residuals because of the large sample size.  The Pearson and standardized Pearson 
residuals were output to a new data set and compared to ensure that their values were equal.  In 
most cases, the values differed only after the first decimal place.  It appears that many of the 
residual values are high (>3.3), however this is not unusual for real life data.  There were actually 
only 21 observations out of the total 964 with a standardized Pearson residual > 3.3 out of 964 
observations.   These 21 observations were printed with their corresponding leverage values and 
Cook’s distance to investigate possible high leverage or influence.  None of these observations 
had high leverage or influence, so these observations were not considered a problem.  The 
leverage and influence plots in Figure 2 also show that none of the observations had very high 
leverage or influence.  These measure potential effects of the observations on the model results. 
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Figure 2: Diagnostic Plots 
 
 
Those without distant metastasis tend to have smaller residuals and leverage, which indicates 
these patients probably have more traits in common.  On the other hand, the distant metastasis 
patients have many more outliers, higher leverage, and residuals, which might indicate that these 
patients are more unique and have many different characteristics.  This observation just 
reinforces the unpredictability of cancer and why it is so difficult to make predictions about the 
disease.  In addition, these disparities might have come about because of the sample size 
differences between the groups.  The local or no metastasis group had 863 observations and the 
distant metastasis group had 101 observations.  Thus it makes sense that since the distant 
metastasis patients are so different from their counterparts, they would have higher leverage 
values.  The sample size disparity also makes sense because distant metastasis is much less 
common for the average breast cancer patient.  A study from the Journal of Clinical Oncology 
reported that a small percentage (31 out of 226, 13.7%) of breast cancer patients with pathologic 
complete response after chemotherapy experience distant metastasis.  This is similar to the 
results in this study, with 101 out of 964 (10.5%) patients experiencing distant metastasis. 
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4. Conclusions 
 
The last part of the analysis for this project includes interpretation and explanations for the 
model results.  From the maximum likelihood estimates, a function for the log-odds of 
developing distant metastasis can be calculated: 
where each variable is 1 if the patient is in that group or 0 if the patient is not.  The variables are: 
 
x1: Disease group “Her2Neu-positive” 
x2: Disease group “Triple-negative” 
x3: Stage “II” 
x4: Stage “III” 
x5: Education level “No college” 
x6: Education level “Unknown” 
x7: Chemotherapy concordance “N/A” 
x8: Chemotherapy concordance “No” 
 
The log-odds of event occurrence is difficult to interpret, so the log-odds function can be 
converted into an odds function using the formula: .  Finally, the probability 
function is then given by .  We end up with the final probability function for this 
analysis: .  This function models 
the probability of a patient developing a distant metastasis, given the characteristic values of the 
patient. 
 
As displayed in Figure 3, triple-negative patients have a consistently higher probability of 
developing distant metastasis, while luminal A patients are much less likely to have distant 
metastasis.  Triple-negative patients have negative estrogen receptors, progesterone receptors, 
and Her2Neu, which means the growth of the cancer is not supported by the hormones estrogen 
and progesterone, nor by the presence of too many Her2Neu receptors.  As a result, triple-
negative breast cancer does not respond to hormonal therapy or other targeted therapies.  Since 
triple-negative patients require unusual treatment courses, it makes sense that these patients 
would be more likely to develop a distant metastasis because they are so different from other 
patients.  On the other hand, luminal A patients are much more common and easier to treat.  
Patients in the luminal A group have markers on their cells to indicate that they will respond well 
the hormone therapies that are common for breast cancer treatment.  These patients generally 
respond better to treatment and are therefore less likely to develop distant metastasis. 
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Figure 3: Probability Plot by Disease Group 
 
 
Figure 4 illustrates the probability of having distant metastasis for patients in the different 
chemotherapy concordance groups.  Patients in the N/A group were consistently less likely to 
have distant metastasis.  This result is unusual and unexpected, which makes it somewhat 
difficult to interpret.  Patients in this group cannot be placed on a guideline due to some 
unknown clinical characteristics so this may just be a chance observation on a group of patients 
with mixed clinical characteristics.  The rates of concordance groupings were evaluated to 
compare the no metastasis patients with the distant metastasis patients across all the variable 
groupings in an attempt to discover why these patients received such an unusual result.  No 
apparent differences were discovered to explain any special characteristics that the N/A patients 
might have.  However, this was expected since there were also no significant interactions.  The 
N/A patients cannot be placed on a guideline due to some missing clinical characteristic or some 
other unknown reason, so it is difficult to explain any reasons these patients might be less likely 
to have a distant metastasis.  Further research is necessary to understand why this result was 
obtained and to investigate whether these results were observed only for this subset of patients. 
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Figure 4: Probability Plot by Chemotherapy Concordance 
 
 
Figure 5 shows probability differences for the stage groups.  It is clear that Stage III patients are 
much more likely to develop distant metastasis.  Stage III patients are more advanced in the 
disease at diagnosis than Stage I patients.  Stage III patients are more advanced because they 
have larger tumors and cancer in more lymph nodes (which allows cancer to spread), but the 
cancer has not actually metastasized yet.  Thus, because Stage III patients are further along they 
are usually harder to treat and have a higher probability of developing distant metastasis. 
 
Figure 5: Probability Plot by Stage 
 
 
As discussed previously, it was found that patients with a college degree were less likely to 
develop a distant metastasis.  This result could be due to patients with a higher education level 
being more informed and more likely to get the treatments they need.  Patients with less 
education may go untreated for longer or not receive the treatment they need at all.  It is also 
 20 
 
possible that patients with more education have better jobs and might have better access to 
healthcare.  There are many explanations for this result, but further research could be used to 
pinpoint the exact reasons.  Figure 6 provides a visual representation of these probability 
differences for education. 
 
Figure 6: Probability Plot by Education Level 
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5. Limitations 
 
This analysis had several limitations.  The first limitation was that recurrence data is difficult to 
come by in breast cancer patients.  These patients have to be followed and observed for long 
periods of time in order to find any recurrence of the disease.  These patients survive long after 
their initial diagnosis so there is a chance patients will drop out of the study for one reason or 
another, or even expire due to another non-breast cancer related cause and before experiencing 
any recurrence.  For this reason, records on distant metastasis can be incomplete and difficult to 
obtain.   
 
In addition, these patients are from a limited sample from the City of Hope.  If there were a way 
to access all patient records, including care at outside clinics, to be sure distant metastasis had or 
had not occurred, this would provide an ideal analysis.  However, this is certainly unrealistic and 
a possible limitation of this study. 
 
Another limitation of this study is lack of knowledge of clinical meaning and in depth knowledge 
of the disease.  It would be ideal to work with a physician to help identify possible predictors, 
because of their knowledge about what contributes to the disease.  Additionally, a physician 
could provide clinical opinions on the analysis and results.  This would allow for better 
interpretation and would significantly strengthen the results. 
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6. Suggestions for further research 
 
Originally, the analysis included an additional research question about whether treatment group 
or disease group is associated with “quicker” time to metastasis.  As proposed, this analysis 
would have included only patients that actually experienced a distant metastasis and investigated 
a regression model, which would have included an age at metastasis variable and a time to 
metastasis variable.  Since the data set for this analysis only included 101 patients with distant 
metastasis, the sample size was not sufficient to conduct such an analysis.  This resulted in a 
more in-depth analysis for the first research question.  However, it would be interesting to 
conduct analysis on this secondary question if provided a larger sample size.  This could be done 
using a disease-free survival analysis to look at time to recurrence.  However, the limited follow-
up information as noted in the limitations section makes this analysis far beyond the scope of this 
research paper. 
 
Another interesting question is what factors influence where the breast cancer spreads?  The 
National Cancer Institute states that the main sites of breast cancer metastasis are the lungs, liver, 
and bones.  It makes sense that cancer would spread to the closest areas to the breast, but perhaps 
there are other reasons for recurrence patterns.  An analysis could be done on patient 
characteristics and clinical variables and with different metastatic sites to see if there is any 
relation between certain these characteristics and their primary metastatic sites.  A larger data set 
would be necessary for this analysis as well. 
 
In addition, much research has been done on gene expression and genetics, and it would be 
interesting to do further research in this area.  The National Foundation for Cancer Research has 
done research on which genes suppress metastasis and how their metastasis-suppressing function 
is regulated, but a more complete understanding has yet to be discovered.  This provides another 
question to be analyzed: whether risk for getting distant metastasis is related to genetics in any 
way.  However, the genetic testing data in this database was very limited. 
 
Research is key to developing new treatments and understandings of this disease.  Continued 
investigation of these research ideas, in addition to other important questions, is essential to 
understanding cancer and working towards preventing and treating it effectively. 
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8. Appendix 
 
The following SAS code was used to carry out this analysis: 
(Please note that the data for this analysis is confidential and is on file with Rebecca Ottesen) 
 
**create libraries for derived and raw data; 
libname ddata 'G:\Senior Project\sasdata\derived'; 
libname rawdata 'G:\Senior Project\sasdata\raw'; 
**tell SAS where to look for format catalogs; 
option fmtsearch=(ddata.ddformats rawdata.formats); 
**Read in Patient Characteristics derived data set; 
data patchar; set ddata.patient_characteristics (drop=cid) 
**delete all patients without Follow-up for Radiation Therapy Analyses; 
if FUrt=1; 
run; 
**Read in Clinical Characteristics derived data set; 
data clnchar; set ddata.clinical_characteristics (drop=cid); 
 **Keep only stage I-III patients; 
  if finalstg>=23 and finalstg<=27.5; 
run; 
**Read in Adjuvant Drug Therapy derived data set: Flags; 
data adjtreat; set ddata.adjuvant_drug_therapy (drop=cid); 
**Create flags indicating if a patient received chemo 
  if adjtxgroup=-99 then delete; 
   else if adjtxgroup in(1,2,6,7) then chemflag=1 
   else chemflag=0; 
run; 
**Read in Metastasis Patient Characteristics derived data set; 
data mets; set ddata.mets_patient_characteristics (drop=cid); 
run; 
**Read in Surgical Information derived data set; 
data surginf; set ddata.surgical_information (drop=cid); 
run; 
**Read in Concordance derived data set; 
data concord; set ddata.concordance_status (drop=cid); 
run; 
**Transpose concordance data to get concordance,guideline,version,nreason 
**rows for each patient; 
proc transpose data=concord out=trconcord; 
  var concordance guideline version nreason;  
  by pid dxid tumorid; 
run; 
**Merge data with itself to get one record per patient; 
data Mconcord; 
  merge trconcord (where=(_NAME_='concordance')  
  keep=pid dxid tumorid _NAME_ COL1-COL4  
  rename=(COL1=Concordance1) rename=(COL2=Concordance2) 
  rename=(COL3=Concordance3) rename=(COL4=Concordance4)) 
trconcord (where=(_NAME_='guideline')  
  keep=pid dxid tumorid _NAME_ col1-col4  
  rename=(COL1=Guideline1) rename=(COL2=Guideline2) 
  rename=(COL3=Guideline3) rename=(COL4=Guideline4)) 
   trconcord (where=(_NAME_='version')  
  keep=pid dxid tumorid _NAME_ col1-col4  
  rename=(COL1=Version1) rename=(COL2=Version2) 
  rename=(COL3=Version3) rename=(COL4=Version4)) 
trconcord (where=(_NAME_='Nreason')  
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  keep=pid dxid tumorid _NAME_ col1-col4  
  rename=(COL1=Reason1) rename=(COL2=Reason2) 
  rename=(COL3=Reason3) rename=(COL4=Reason4)); 
  by pid dxid tumorid; 
run; 
**Read in Metsites raw data set; 
data metsite; set rawdata.metastatic_sites (drop=cid studyid) 
if initial=0 and ((site in(5,6,7,8,9,10,11,12,13,15,17,18,19,20)) 
or (site=16 and sitedt<mdy(1,1,2003))) 
   then DistMet=3; **Distant Met; 
  else if site~=. then DistMet=2; **Local Met; 
run; 
**Read in Study Accession raw data set; 
data stdyacc; set rawdata.study_accession (drop=cid studyid); 
run; 
**Create format for new insurance variable, store in ddformats catalog; 
proc format library=ddata.ddformats; 
  value newins 
   .='Missing' 
  -1='Unknown' 
   0='Other' 
  1='Managed' 
  2='Indemnity' 
  4='Medicaid/Indigent' 
  5='Medicare alone' 
  5.5='Medicare + Supp' 
  5.75='Medicare + Managed' 
  6='Self-Pay'; 
run; 
**Read in Insurance raw data set; 
data insurance; set rawdata.insurance (drop=cid studyid); 
  if assessid=0; **keep only first record of insurance; 
  *** reprogram insurance;  * per MH grid 043003; 
  if ins1type=2 or ins2type=2 then do; 
    if ins1type~=5 and ins2type~=5 then newinsur=2; 
    else if ins1type=5 or ins2type=5 then newinsur=5.5; 
  end; 
  else if ins1type=1 or ins2type=1 then do; 
if ins1type not in(4,5) and ins2type not in(4,5) then 
newinsur=1; 
else if ins1type=5 or ins2type=5 then newinsur=5.75;  
* medicare+managed; 
    else if ins1type=4 or ins2type=4 then newinsur=4; 
  end; 
  else if ins1type in(4,7) or ins2type in(4,7) then do; 
    if ins1type~=5 and ins2type~=5 then newinsur=4; 
   else if ins1type=5 or ins2type=5 then newinsur=5.5; 
  end; 
  else if ins1type=6 or ins2type=6 then do; 
    if ins1type~=5 and ins2type~=5 then newinsur=6; 
   else if ins1type=5 or ins2type=5 then newinsur=5.5; 
  end; 
  else if ins1type in(0,3,8,9,10,11) or ins2type in(0,8,3,9,10,11) 
then do; 
    if ins1type~=5 and ins2type~=5 then newinsur=0; 
    else if ins1type=5 or ins2type=5 then newinsur=5.5; 
  end; 
  else if (ins1type in(-1) and ins2type in(-1,.)) or  
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(ins1type in(-1,.) and ins2type in(-1)) then newinsur=-1; 
  else if ins1type=5 and ins2type in(0,5) then newinsur=5.5; 
  else if ins1type=5 and ins2type in(-1,.) then newinsur=5; 
  else if ins1type in(-1,.) and ins2type=5 then newinsur=5; 
  else if ins1type=. and ins2type=. then newinsur=.; 
  format newinsur newins.; 
run; 
**Read in Solid Tumor Stage raw data set; 
data ststge; set rawdata.solid_tumor_stage (drop=cid studyid); 
run; 
**Read in raw Treatment data set where txcat=10(radiation) and indication 
**in(1,2,3,4); 
data treat; set rawdata.treatment (drop=cid studyid); 
  if txcat=10; 
  where indication in(1,2,4);  
run;   
**Merge data by pid dxid and tumorid; 
data merge1; 
  merge clnchar (in=a) ststge surginf Mconcord;  
  by pid dxid tumorid; 
  if a=1 then output;   
**only keeps narrowed down records from derived data (one record 
**per patient); 
run; 
**Merge data by pid and dxid; 
data merge2; 
  merge merge1 (in=a) treat adjtreat mets metsite; 
  by pid dxid; 
  if site=. then DistMet=1;  **define no met; 
  if a=1 and side=laterality then do; 
   **flag patients as having radiation if side=laterality 
   rtflag=1; 
   output; 
  end; 
  else if a=1 then do; 
   **otherwise keep narrowed records and flag no radiation 
   rtflag=0; 
   output; 
  end; 
run; 
**sort to pick distant sites trumping other sites; 
proc sort data=merge2; 
  by pid dxid distmet; 
run; 
**overwrite merge 2 to narrow down one row per patient by keeping last 
**diagnosis record; 
data merge2; set merge2; 
 by pid dxid distmet; 
 if last.dxid=1; 
run; 
**Merge data by pid; 
data mergelast; 
 merge patchar (in=a) merge2 (in=b) stdyacc insurance; 
 by pid; 
if a=1 and b=1 then output;   
**only keeps narrowed down records from derived data; 
run; 
**Check to see if there is more than one of the same value for a variable; 
 27 
 
proc freq data=mergelast noprint; 
  table pid / out=count; 
run; 
**print pid's with repeats; 
proc print;  
 where count>1; 
run; 
**Define formats, save to derived data format catalog; 
proc format library=ddata.ddformats; 
 **Disease Groups format; 
 value tripneg 
  3='TripNeg' 
  2='Her2' 
  1='LumA'; 
 **Treatment Groups format; 
 value treatgrp 
  1='RT alone' 
  2='RT+Chemo' 
  3='Chemo alone'; 
 **Distant Met Definition format; 
 value dist 
  1='Distant Metastasis' 
  0='Local or no met'; 
 **BMI group format; 
 value bmi 
  1='Underweight' 
  2='Normal' 
  3='Overweight' 
  4='Obese'; 
 **RT/Chemo Concordance variable format; 
 value rtchconc 
  3='N/A' 
  1='Yes' 
  2='No'; 
 **Age group format; 
 value age 
  1='Below 50' 
  2='50-70' 
  3='Above 70'; 
 **Stage variable format; 
 value stage 
  1='I' 
  2='II' 
  3='III'; 
 **Race variable format; 
 value rce 
  1='Caucasian' 
  2='Hispanic' 
  3='African American' 
  4='Other'; 
 **Education variable format; 
 value edu 
  2='Col' 
  1='NoCol' 
  3='Unkn'; 
 **Employment variable format; 
 value emp 
  1='Employed' 
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  2='Student' 
  3='Other'; 
 **Insurance variable format; 
 value insur 
  1='Managed' 
  2='Medicare' 
  3='Medicaid' 
  4='Other'; 
run; 
**Create analysis data set from final data set; 
data analysis exclude; set mergelast  
 (keep=pid dxid tumorid her2neu metage diagage distmet finalstg dsgroup 
  racecomp p053001 edustat empstatdx initial ins1type ins2type newinsur 
 site furt laterality adjtxgroup indication side heightpres weightpres 
 chemflag rtflag tmarker1 tmarker2 concordance: guideline:); 
 **create disease groups; 
if tmarker1 in(.,-1) or tmarker2 in(.,-1) or Her2neu in(.,-1) 
then delete; 
else if tmarker1=0 and tmarker2=0 and (her2neu in(1,2)) then 
DiseaseGrp=3; 
  else if her2neu in(3,4) then DiseaseGrp=2; 
  else DiseaseGrp=1; 
 **redifine distmet and combine local/no met for logistic regression; 
  if distmet=3 then distmet=1; 
   else if distmet=2 or distmet=1 then distmet=0; 
 **create BMI variable; 
  if heightpres~=-1 then do; 
   heightM=heightpres/100; 
   BMI=weightpres/(heightM**2); 
  end; 
 **create BMI groups;  
  if BMI<18.5 then BMIGrp=1; 
  else if BMI>=18.5 and BMI<25 then BMIGrp=2; 
  else if BMI>=25 and BMI<30 then BMIGrp=3; 
  else if BMI>=30 then BMIGrp=4; 
 **create variables to test for linearity in the logit; 
  linage=diagage*log(diagage); 
  if p053001>=0 then lininc=p053001*log(p053001); 
  if bmi~=. then linbmi=bmi*log(bmi); 
 **Define concordance variable; 
  array conc (4) concordance:; 
  array guide (4) guideline:; 
  RTConcord=0; 
  ChemoConcord=0; 
  do i=1 to 4; 
   if conc(i)='Yes' and (substr(guide(i),1,4)='invx' or 
guide(i)='invtx1' or guide(i)='invtx1b' or  
guide(i)='invtx1c') then RTConcord=rtconcord+1; 
   if conc(i)='Yes' and (substr(guide(i),1,4)='inva' or 
guide(i)='invtx1' or guide(i)='invtx1b' or 
guide(i)='invtx1c' or guide(i)='invtx1a' or  
guide(i)='invtx2') then ChemoConcord=chemoconcord+1; 
  end; 
 **Break down no guideline/not on inva,invx guideline and not concord; 
  if (chemoconcord=0 or rtconcord=0) and guide(1)~='Not evaluated 
  for concordance' then do i=1 to 4; 
   if conc(i)='No' and (substr(guide(i),1,4)='invx' or 
guide(i)='invtx1' or guide(i)='invtx1b' or 
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guide(i)='invtx1c') then rtconcord=2; 
   if conc(i)='No' and (substr(guide(i),1,4)='inva' or 
guide(i)='invtx1' or guide(i)='invtx1b' or  
guide(i)='invtx1c' or guide(i)='invtx1a' or 
guide(i)='invtx2') then chemoconcord=2; 
  end; 
  if chemoconcord=0 then chemoconcord=3; 
  if rtconcord=0 then rtconcord=3; 
 **Create groupings for Age variable; 
  if diagage<50 then AgeGroup=1; 
  else if diagage>=50 and diagage<=70 then AgeGroup=2; 
  else AgeGroup=3; 
 **Collapse stages into I,II,III only; 
  if finalstg>=23 and finalstg<=23.2 then Stage=1; 
  else if finalstg>=23.5 and finalstg<=25 then Stage=2; 
  else if finalstg>=25.5 and finalstg<=27.5 then Stage=3; 
 **Collapse race into Caucasian, Hispanic, African American or other; 
  if racecomp=1 then Race=1; 
  else if racecomp in(2,11,8,6,4) then Race=2; 
  else if racecomp=3 then Race=3; 
  else Race=4; 
 **Collapse education variable into College, no college, unknown; 
  if edustat in(5,6,7) then Education=2; 
  else if edustat in(1,2,3,4) then Education=1; 
  else Education=3; 
 **Collapse employment variable into employed, student, other; 
  if empstatdx in(1,2,5) then Employment=1; 
  else if empstatdx in(3,4) then Employment=2; 
  else Employment=3; 
 **Collapse insurance variable; 
  if newinsur=1 then Insurance=1; 
  else if newinsur in(5,5.5,5.75) then Insurance=2; 
  else if newinsur=4 then Insurance=3; 
  else Insurance=4; 
 **create treatment groups and output to analysis/exclusions data sets; 
  if chemflag=1 and rtflag=1 then do; 
   TreatGroup=2; 
   output analysis; 
  end; 
  else if rtflag=1 then do; 
   TreatGroup=1; 
   output analysis; 
  end; 
  else if chemflag=1 then do; 
   TreatGroup=3; 
   output analysis; 
  end; 
  **create exclusions output to check; 
  else output exclude; 
 **create significant variable labels; 
  label DiseaseGrp="Disease Group" distmet="Distant Metastasis" 
chemoconcord="Chemotherapy Concordance"  
Stage="Stage at Diagnosis" Education="Education Level"; 
 **format variables 
format diseasegrp tripneg. distmet dist. bmigrp bmi. Rtconcord 
rtchconc. chemoconcord rtchconc. agegroup age. stage stage. 
race rce. education edu. employment emp. insurance insur. 
treatgroup treatgrp.; 
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 **only keep variables of interest for analysis 
keep pid distmet diagage p053001 bmi bmigrp agegroup treatgroup 
diseasegrp stage dsgroup race education employment 
insurance rtconcord chemoconcord; **linbmi linage lininc ; 
run; 
**Run proc freq on categorical variables; 
proc freq data=analysis; 
  tables distmet diseasegrp*distmet stage*distmet education*distmet 
chemoconcord*distmet agegroup*distmet bmigrp*distmet 
treatgroup*distmet dsgroup*distmet race*distmet 
employment*distmet insurance*distmet rtconcord*distmet / 
norow nopercent; 
run; 
**Run logistic regression analysis; 
**Q: Are triple negs (TN) or treatment group (TG) associated with having 
**distant metastasis?; 
**also account/control for stage, age at diagnosis, and other socio-economic 
**status variables; 
ods graphics on; 
proc logistic data=analysis plots=all; 
class distmet (ref='Local or no met') diseasegrp (ref='LumA') 
stage(ref='I') education (ref='Col')  
chemoconcord (ref='Yes') / param=ref;  
  model distmet = diseasegrp stage education chemoconcord  
   / lackfit aggregate scale=n rsquare stb iplots clodds=pl;  
label diseasegrp='Disease Group' stage='Stage at  
Diagnosis' 
education='Education Level' chemoconcord='Chemotherapy 
Concordance'; 
run; 
ods graphics off; 
**logistic regression for creating effects plots; 
ods graphics on; 
proc logistic data=analysis plots(only)=effect(sliceby=chemoconcord  
connect); 
*sliceby=diseasegrp sliceby=stage sliceby=education; 
*sliceby=chemoconcord ; 
  class distmet (ref='Local or no met')  diseasegrp  stage 
   education   chemoconcord/ param=ref;  
  model distmet = diseasegrp stage education chemoconcord;  
run; 
ods graphics off; 
**Genmod procedure for residuals; 
ods graphics on; 
proc genmod data=analysis plots=(stdreschi reschi leverage dobs); 
 class distmet (ref='Local or no met')  diseasegrp (ref='LumA') 
stage (ref='I') education (ref='Col') chemoconcord 
(ref='Yes') / param=ref;  
  model distmet = diseasegrp stage education chemoconcord / 
link=logit dist=bin;  
  output out=resids reschi=pearson stdreschi=stdpearson 
leverage=lev cookd=infl; 
run; 
ods graphics off; 
**Print observations with high residuals 
proc print data=resids; 
var pid distmet pearson stdpearson lev infl; 
  where stdpearson>3.3; 
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run; 
**Check for multicollinearity of predictors; 
ods graphics on; 
proc corr data=analysis spearman; 
var diseasegrp stage education chemoconcord; 
run; 
ods graphics off; 
**Investigate possible reasons patients not on a NCCN guideline are less 
**likely to develop a distant met; 
proc freq data=analysis; 
 where distmet=1; *where distmet=0; 
 tables chemoconcord diseasegrp*chemoconcord stage*chemoconcord 
education*chemoconcord; 
run; 
